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Abstract
Background: People with anxiety disorders represent a significant part of a general practitioner’s patient population.
However, there are organisational obstacles for optimal treatment, such as a lack of coordination of illness management
and limited access to evidence-based treatment such as cognitive behavioral therapy. A limited number of studies
suggest that collaborative care has a positive effect on symptoms for people with anxiety disorders. However, most
studies are carried out in the USA and none have reported results for social phobia or generalised anxiety disorder
separately. Thus, there is a need for studies carried out in different settings for specific anxiety populations.
A Danish model for collaborative care (the Collabri model) has been developed for people diagnosed with depression
or anxiety disorders. The model is evaluated through four trials, of which three will be outlined in this protocol and
focus on panic disorder, generalised anxiety disorder and social phobia. The aim is to investigate whether treatment
according to the Collabri model has a better effect than usual treatment on symptoms when provided to people with
anxiety disorders.
Methods: Three cluster-randomised, clinical superiority trials are set up to investigate treatment according to the
Collabri model for collaborative care compared to treatment-as-usual for 364 patients diagnosed with panic disorder,
generalised anxiety disorder and social phobia, respectively (total n = 1092). Patients are recruited from general
practices located in the Capital Region of Denmark. For all trials, the primary outcome is anxiety symptoms (Beck
Anxiety Inventory (BAI)) 6 months after baseline. Secondary outcomes include BAI after 15 months, depression
symptoms (Beck Depression Inventory) after 6 months, level of psychosocial functioning (Global Assessment of
Functioning) and general psychological symptoms (Symptom Checklist-90-R) after 6 and 15 months.
Discussion: Results will add to the limited pool of information about collaborative care for patients with anxiety
disorders. To our knowledge, these will be the first carried out in a Danish context and the first to report results
for generalised anxiety and social phobia separately. If the trials show positive results, they could contribute to
the improvement of future treatment of anxiety disorders.
(Continued on next page)
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Background
Across surveys, anxiety disorders are found to be the
most prevalent group of mental disorders in the gen-
eral population, with an estimated lifetime prevalence
of 16% on average for any anxiety disorder [1].
Among patients with anxiety disorders, there is a high
level of comorbidity with other psychiatric disorders
such as other anxiety disorders, depression and alco-
hol abuse [2–4], but also physical illnesses [5, 6]. The
human costs related to anxiety disorders are high and
place a significant burden on the economy due to
high levels of health care use, lost income and sick
leave. In Denmark, the total cost related to anxiety
disorders is estimated to be six billion DKK per year
[7], approximately US$900 million.
The majority of patients with anxiety disorders in
Denmark are treated in general practice [8]. For general
practitioners (GPs), people with anxiety disorders repre-
sent a significant part of their patient population as they
use health care services more frequently compared to
patients without anxiety disorders [9–11]. It is estimated
that 1–7% of the patients in general practice have panic
disorder [12–14], 4–12% have generalised anxiety disorder
[3, 12, 13, 15] and 4–6% have social phobia [3, 13].
Patients with non-psychotic disorders, such as anxiety
disorders, are poorly recognised and often not treated suf-
ficiently [3, 15–22]. The main obstacles for adequate treat-
ment are poor coordination between sectors and a lack of
competent treatment availability in general practice [23].
Cognitive behavioural therapy (CBT) is an evidence-based
treatment for anxiety disorders and recommended in treat-
ment guidelines [19, 24]. In Denmark, GPs can refer
patients either to an independent psychologist through an
existing public scheme, which includes up to 24 sessions
with partly subsidised fees for patients between 18 and 38
years, or a public insurance-paid independent psychiatrist,
where they often have to wait for months due to long wait-
ing lists [23]. GPs can offer a limited number of sessions of
psychotherapy, but only if they receive supervision [25]. It
is estimated that only around one third of GPs fulfil these
requirements [23, 26–28]. Furthermore, there is no train-
ing in psychotherapy in GPs’ specialist training and no
requirements for the GP to participate in postgraduate
training to improve their skills and ensure that they are
continuously updated and provide a high quality of care.
This treatment gap calls for more accessible evidence-
based treatment opportunities in general practice.
Danish guidelines for anxiety disorders and depression
suggest that improving the treatment in general practice
should be done by introducing shared-care interventions
such as collaborative care programs [19, 29]. Collaborative
care models for anxiety disorders and depression are com-
plex interventions; however, there are four criteria which
should be fulfilled: (1) a multi-professional approach to
treatment, (2) scheduled follow-up, (3) enhanced interpro-
fessional communication and (4) treatment according to a
structured treatment plan [30].
Studies on collaborative care for anxiety disorders are
limited. According to a Cochrane review from 2012,
collaborative care between the primary and secondary
care system provides a useful addition to clinical path-
ways for the treatment of anxiety disorders and depres-
sion and shows significant improvements in treatment
outcomes for up to 2 years compared with treatment-as-
usual in general practice [30]. However, the review only
included four studies reporting results for panic disorder,
generalised anxiety disorder or social phobia and they
were all conducted in the USA [31–34]. A recent review
updated the evidence base for anxiety disorders [35] and
included an additional three studies from Germany and
The Netherlands [36–38] and also found collaborative
care superior to treatment-as-usual, with a small effect
size for all anxiety disorders combined and a moderate
effect size in a subgroup of studies on patients with
panic disorder. Additional analysis in the review [35]
also showed a greater effect size in studies performed in
the USA compared to studies performed in Europe in
studies that included a care manager and in studies
using stepped collaborative care, although this is to be
interpreted with caution due to the small number of
studies and the heterogeneity between the European
studies. Thus, current evidence builds on few studies all
conducted in organisational settings not comparable
with the Danish or Scandinavian ones. Furthermore, no
studies report results for social phobia or generalised
anxiety disorder separately. Therefore, there is a need
for further research into collaborative care models
facilitating a more effective implementation of the
intervention as well as for specific anxiety populations
in different organisational contexts.
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The development of a Danish model for collaborative
care (the Collabri model) for panic disorder, generalised
anxiety disorder and social phobia was completed in
2014 in collaboration between Danish GPs, psychiatrists
and researchers. In this paper the protocol (version 2)
for three cluster-randomised controlled, superiority trials
investigating collaborative care, according to the Collabri
model, vs. treatment-as-usual for panic disorder, general-
ised anxiety disorder and social phobia will be outlined.
As we developed specific collaborative care treatment
models for each of the three anxiety disorders, and
wanted to examine the effect of each of these three
collaborative treatment models, we designed three
cluster-randomised controlled, superiority trials; but as
the trials for each of three anxiety disorders are similar
in terms of aim, design and methods, they are jointly
presented in this paper. The hypothesis for each of the
trials is that treatments according to the Collabri model
are more effective than treatment-as-usual.
Methods
Aim and design
The aim of the three trials is to test if treatment accord-
ing to the Collabri model is more effective than
treatment-as-usual. The null hypothesis for each trial to
be rejected is that collaborative care according to the
Collabri model (intervention group) and treatment-as-
usual (control group) have the same effect on anxiety
symptoms for patients with panic disorder, generalised
anxiety disorder and social phobia in general practice. The
trials are designed as three independent, two-armed,
cluster-randomised, clinical superiority trials (see the flow
chart in Fig. 1). All aspects of the study design (including
assessment time points, outcome measures, etc.) are iden-
tical in the three trials. A total n = 1092 is required based
on sample size calculations; 364 patients in each of the
three trials (diagnoses) on panic disorder, generalised
anxiety disorder and social phobia, respectively.
Eligibility criteria for participants
Cluster level
GPs with a registered provider number, practicing in the
Capital Region of Denmark, are eligible for the trials.
For practical reasons, GPs on the island of Bornholm are
not eligible. The local branch of the Organisation of
General Practitioners in Denmark and the Capital
Region of Health Care have negotiated and signed an
agreement that allows the GPs to participate in the study
and sets out the terms and conditions for it, including
financial reimbursement.
Individual level
Patients are eligible for the trials if they consult a GP
who is participating in the trials and additionally comply
with the inclusion and exclusion criteria. These criteria
are assessed by the GP at recruitment and/or a research
assistant at a baseline eligibility interview.
Inclusion criteria Participating patients should be at
least 18 years old, diagnosed in general practice according
to the International Classification of Diseases 10th edition
(ICD-10) criteria for panic disorder (F41.0), generalised
anxiety disorder (F41.1) or social phobia (F40.1) [39]. They
must speak Danish and give their written consent to
participation.
Exclusion criteria Patients cannot participate in the trials
if they are pregnant, have a pending disability pension
application, are at a high risk of suicide, have a current
psychotic condition, obsessive compulsive disorder, or
bipolar affective disorder, misuse alcohol or other sub-
stances to an extent that will hinder the patient’s participa-
tion in treatment, if they receive current psychological or
psychiatric treatment for depression or anxiety or have
been receiving such treatment within the last 6 months.
Also, referral to the secondary care system before or at the
first GP consultation after baseline eligibility interview,
because of a need for more specialised care, is a reason for
exclusion. Furthermore, patients cannot participate if it is
clinically assessed by the GP that they have dementia or
an unstable medical condition that hinders the patient
from adhering to treatment. Patients in the intervention
group are excluded if they want treatment according to
the existing public psychologist scheme and do not want
referral to the psychologist to be preceded by treatment
according to the Collabri model.
Exclusion criteriaRecruitment and randomisation
Cluster level
The GP recruitment period lasted from May 2014 until
July 2015. GP practices were invited to participate via
postal letters. This included easy-to-read information
about the project and an invitation to attend information
meetings. Eligible GPs were randomised to either provide
treatment according to the Collabri model or treatment-
as-usual. A cluster corresponds to a GP provider number
which may include one or several GPs. Cluster-
randomisation was chosen, as a significant risk of bias was
identified in the form of contamination if randomisation
was performed on patient level. Randomisation was per-
formed externally by The Research Centre for Prevention
and Health (RCPH) in the Capital Region of Denmark,
which used a centralised computer-generated allocation
sequence. The randomisation was conducted in two
phases. The first included 49 GPs and was stratified by
three geographically defined uptake areas. The second
randomisation included four GPs, and here a geographical
stratification was not used.
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Individual level
As the trial is randomised on general practice level, the
participating patients are allocated to either the inter-
vention or control group according to their GP. The
GPs identify and recruit the patients with anxiety disor-
ders. In Danish medical guidelines GPs are recom-
mended to use the Anxiety Symptom Scale (ASS) in
conjunction with ICD-10 criteria for diagnostic investi-
gation [24]. The GP provides written and verbal infor-
mation about the project, and hands out the Consent
Form. Following recruitment, a research assistant
contacts the patient to schedule a telephone baseline
eligibility interview. The aim is to assess inclusion and
exclusion criteria and verify the GP’s diagnosis by
conducting a diagnostic interview. If the diagnosis accord-
ing to the diagnostic interview differs from the diagnosis
given by the GP, the research assistant consults a psych-
iatrist in the Collabri team who contacts the GP in order
to discuss and agree on the diagnosis. Patient recruitment
was initiated in November 2014 and ended on 31 Decem-
ber 2016.
Blinding
The research team (who assess baseline eligibility criteria,
collect interviewer-based baseline and follow-up assess-
ments, perform statistical analyses and draw conclusions)
are blinded to allocation throughout the entire trial period
(from baseline eligibility interview to drawing
Fig. 1 Flow chart for participants. Each trial has a flow chart similar to this
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conclusions). It is not possible to blind GPs, the Collabri
team who deliver the intervention, the administrative pro-
ject team and the participating patients towards interven-
tion allocation. It will be highlighted to them that they
cannot reveal their allocation group to the research team.
Should the allocation be revealed to the research assistant
before assessments (baseline eligibility interview or
interviewer-based assessments), another research assistant
is allocated. Furthermore, during statistical analyses, the
two groups will be coded and anonymised (e.g., X and Y)
until final analyses and conclusions have been made.
The referral diagnosis is not revealed to the researchers
conducting the baseline eligibility interview until the end
of the interview. This makes the assessment of baseline
eligibility criteria more objective.
Interventions
The experimental intervention – the Collabri model for
collaborative care
The Collabri model is developed based on the previously
mentioned four criteria for collaborative care [30] and
has been adapted to Danish conditions by including
collaboration with relevant professionals in the local
authorities and integrating the existing public psycholo-
gist scheme. In addition, the model integrates elements
which are found to be essential for collaborative care
interventions in an academic literature review [40] or
recommended in current guidelines [19, 24, 41] recom-
mending the use of screening instruments for detection
and follow-up, and a stepped-care approach to treatment.
In addition, the model incorporates principles of involve-
ment of relatives, patient involvement and influence on
treatment and support in self-management. Below, how
the Collabri model meets the four criteria for collaborative
care is outlined.
The model includes a multi-professional approach to
treatment involving a GP, a care manager and a psychi-
atric specialist. Interprofessional communication consist
of weekly meetings between the GP and care manager in
order to discuss clinical cases and of the psychiatric
specialist supervising the care managers in groups twice
a month and the GPs in groups once a month. When
needed, the GP, care manager and the psychiatric
specialist have joint consultations and the GPs and care
managers receive individual supervision from the psychi-
atric specialist if required. The weekly meetings between
care manager and GP take place in person, but other
communication can take place via video conferences if it
is not possible to meet in person.
It has not been possible to establish a joint recording
system between primary and secondary care systems;
however, written communication between the GP and
care manager or psychiatric specialist occurs through
already existing electronic communication systems.
All patients commence their treatment by developing an
individually structured treatment plan which is based on
disorder-specific manuals (unpublished, available through
the corresponding author) following the stepped-care
principle and complying with national guidelines [19, 24],
see Fig. 1. The core treatment elements of the model are:
disorder-specific written material and a self-management
book (bibliotherapy), CBT, group-based or individual
manualised psychoeducation based on the Chronic
Disease Management Program (CDSMP)) or as a part of
CBT, individual CBT (10–12 sessions, depending on
disease) and/or medication. The treatment period is 3–4
months. The number of sessions in the Collabri group will
be obtained and reported.
Depending on the disorder and severity, the patients
will be offered treatment elements according to a
stepped-care plan, offering the least invasive and least
resource-demanding treatment first (stepwise scaling up
of treatment efforts) (see Fig. 1).
The care manager ensures active and scheduled
follow-up including regular monitoring and review of
progression. Monitoring takes place as a minimum
every 2 weeks or more often depending of the severity
of the disorder or when medication is initiated. Regular
reviews of the treatment plan will take place at least
once a month, and must precede stepping up as well as
ending treatment.
The multi-professional Collabri team In the Collabri
treatment, the GP works in combination with the Collabri
team (the care manager and the psychiatrist/psychologist)
around the treatment of the patient). The GP has the
overall treatment responsibility, including the diagnostic
process, initiates the treatment and collaborates with the
care manager to provide seamless treatment and care.
The Collabri team is a health care team consisting of
care managers and psychiatric specialists. The psychiatric
specialists can either be psychiatrists or psychiatrists in
combination with a psychologist with specialist training in
psychiatry. The care managers have a medium-long health
professional education; for example, as a nurse with men-
tal health care experience as well as being certified in
providing CBT (the minimum requirement is a 1-year
recognised course). Care managers, GPs and the psychia-
trists ensure adherence to the Collabri model.
Training prior to intervention All care managers
attend a 1-week course introducing them to the Collabri
model and the CBT methods. In addition they attend a
4-day training course leading to certification in a manua-
lised group-based psychoeducation program (based on
the Chronic Disease Management Program (CDSMP)),
and an additional 2-day course of introduction in an
individualised psychoeducation manual based on the
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CDSMP principles. The psychiatric specialists also
attend the training except the group psychoeducation
training. All GPs in the intervention group participate in
a 1-day training course in the principles of collaborative
care and the Collabri model.
Fidelity Fidelity assessments ensure that the Collabri
intervention is carried out according to the described
Collabri model. Assessors will monitor fidelity to the
model 6 months after study initiation and at least once
more during the inclusion period. Fidelity will be moni-
tored using a Collabri fidelity scale (unpublished, available
through the corresponding author). In order to improve
implementation, an action plan will be developed where
needed based on the outcome of the fidelity assessments.
The control intervention – treatment-as-usual
Participants whose GP is randomised to the control group
will receive treatment-as-usual as offered by their GP.
Guidelines from the Danish Health Authority and The
Danish College of General Practitioners are available for
guidance [19, 24]. According to the guidelines a physical
health evaluation is performed prior to diagnosis and the
ASS instrument in conjunction with ICD-10 criteria is
recommended for detection, diagnostic investigation and
monitoring of the disorder [42]. If relevant, the GP can
prescribe medication and/or provide psychotherapy if they
attend supervision. The GP can also refer patients to an
independent psychologist (partly publicly subsidised) or to
a public psychiatrist or to treatment in the secondary
health care system (fully publicly subsidised). Accessible
treatment can vary between general practices as these
guidelines only provide recommendations for treatment
or management of the disorders, as opposed to required
minimum standards.
Assessments and outcome measures
Baseline eligibility interview
At baseline, patients attend a telephone eligibility interview
where the inclusion and exclusion criteria are assessed by
a research assistant. To confirm the diagnosis the Diagnos-
tic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) MINI International Neuropsychiatric Interview
[43] is used including ICD-10-specific questions, for the
inclusion diagnoses. The GP assesses comorbidity at
recruitment. Information on personality disorder traits are
obtained through the Standardised Assessment of Person-
ality: Abbreviated Scale (SAPAS) [44].
Outcome measures
Participants are interviewed and asked to fill out a ques-
tionnaire at baseline, 6 and 15 months’ follow-up. In the
following each assessment instrument will be described.
See the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) figure (Fig. 2) for an over-
view of time schedule, assessment instruments and source
of data collection.
Primary outcome measure The primary outcome is anx-
iety symptoms measured with the Beck Anxiety Inventory
(BAI) 6 months after baseline. The BAI is a 21-item
general questionnaire for anxiety, measuring symptoms
during the last week rated on a four-point Likert-scale
from 0 (never) to 3 (almost all the time), where the
maximum score is 63 [45]. The BAI has shown excel-
lent psychometric properties, with internal consistency:
α = 0.92 and 1-week test-retest reliability: r = 0.75 in a
community sample [46].
Secondary outcome measures The secondary outcome
measures are the BAI at 15 months, depression symptoms
(Beck Depression Inventory (BDI-II)) [47] at 6 months,
level of psychosocial functioning (Global Assessment of
Functioning (GAF-F)) [48] and general psychological
symptoms (Symptom Checklist (SCL-90-R)) [49] at 6 and
15 months after baseline.
The BDI-II is a 21-item general questionnaire for
measuring depression symptoms during the last 14 days
rated on a four-point Likert-scale from 0 to 3, where the
maximum score is 63. A meta-analysis of the BDI II’s
internal consistency estimates yielded a mean coefficient
alpha of 0.86 for psychiatric patients and 0.81 for non-
psychiatric subjects [50]. The test-retest reliability for
the BDI II for psychiatric patients has been reported to
range from 0.48 to 0.86, and for non-psychiatric subjects
from 0.60 to 0.83. The SCL-90-R is the revised version
of SCL-90, a multi-dimensional questionnaire consisting
of 90 questions about general psychological symptoms.
The questionnaire consists of nine subscales from which
a joint measure (Global Severity Index (GSI)) can be
calculated. The internal consistencies of the SCL-90-R
are satisfactory with range from α = 0.74 (‘aggression’)
to α = 0.97 (GSI) [51].
The split version of the GAF on psychosocial function-
ing ranges from 0 to 100 points, with a higher number
indicating a higher level of functioning. Studies suggest a
good validity of the GAF-F scale as well as usefulness of
measuring the level of psychosocial functioning among
incident patients with schizophrenia. A high inter-rater
reliability can be achieved with little training of the
raters [52].
Explorative outcome measures The explorative out-
come measures are the BDI-II at 15 months, personal
and social performance (PSP) [52], health-related qual-
ity of life (EQ-5D-3 L) [53], functional impairment
(Sheehan Disability Scale (SDS)) [54], quality of life
(WHO-five Well-being Index (WHO-5)) [55] and self-
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efficacy (Personal Control subscale from the revised
version of the Illness Perception Questionnaire (IPQ-R)
[56] and two subscales from the Chronic Disease Self-
Efficacy Scales (SECD-32); and the Obtain Help from
Community, Family, Friends Scale and Control/Manage
Depression Scale) [57] at 6 and 15 months.
Here, a measure of apathy will also be collected
through the Diagnostic Apathia Scale, which consists of
six items [58] and side effects from treatment will be
measured with the Patient-Rated Inventory of Side
Effects (PRISE) which identifies and evaluates the toler-
ability of symptoms/side effects in nine domains [59].
The PSP measures personal and social functional level
in the domains of: socially useful activities (for example,
work and education), personal and social relationships,
self-care and disturbing and aggressive behaviours on a
scale from 1 to 100 with a higher number indicating
higher level of function.
The EQ-5D-3 L is a measure of health status in five do-
mains: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression and also includes a Visual
Analogue Scale from 0 (worst imaginable health status) to
100 (best imaginable health status).
The SDS is a composite of three items designed to
measure the extent to which three major domains in
the patient’s life are impaired by symptoms, and can
be summed into a joint measure of global functional
impairment that ranges from 0 (unimpaired) to 30
(highly impaired). The WHO-5 consists of five items
that measure the subjective experience of quality of
Fig. 2 Time schedule, assessment instruments and source of data collection
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life or psychological wellbeing. Each item is rated on
a six-point Likert scale from 0 (not present) to 5
(constantly present).
The IPQ-R has 12 subscales of which the Personal
Control subscale consists of six items about one’s own
beliefs about the ability to affect the disorder. Each item
is rated on a five-point Likert-scale from 1 (disagree very
much) to 5 (agree very much).
The two subscales of SECD-32 consist of four and six
items about how confident one is in doing certain activ-
ities. Each item is rated on a 10-point Likert scale from
one (not at all confident) to 10 (very confident).
Information about life-threatening conditions, the use
of inpatient and outpatient physical and mental health
services and number of days of admission and former
treatment is collected through the National Patient
Registry which holds information about all patient con-
tacts in the secondary health care system [60].
Medication use is retrieved from the Danish National
Prescription Registry which holds information about all
sales of medication [61].
Information about deaths is collected through The
Danish Register of Causes of Death, which is based on
information of all deaths in Denmark since 1943 [62].
Sickness leave, employment and use of other social
services will be obtained from the Danish Register for
Evaluation of Marginalisation (DREAM), which contains
information about contact with the labour market for
the entire Danish population [63]. These data are
collected at baseline, 6 and 15 months.
At 6 months the patient’s feeling of being supported in
their recovery by their primary health care provider (care
manager and GP in the intervention group and GP in the
control group) is assessed through the INSPIRE question-
naire, which has two sections – one about support (20
items) and one about relationship (seven items) [64].
Participants also rate their general satisfaction with
treatment through the CSQ-8 questionnaire [65] together
with project-specific questions. The CSQ-8 consists of
eight items which are rated on a scale from 0 to 4.
Baseline information, such as former treatment, educa-
tion and marital status, will be collected through Statistics
Denmark, which is the central authority on Danish statis-
tics [66], and the National Patient Registry.
Data collection
Interview-based assessments such as the GAF-F and
the PSP will be conducted through telephone inter-
views by research assistants who are thoroughly trained
in using the instruments. Other data are collected
either through self-reported questionnaires or registers
(see Fig. 2 for details of sources of data collection).
Self-reported questionnaires are completed online or in
a paper version. If participants have not completed the
questionnaire after 8 days, they will be reminded and, if
necessary, they will be contacted in order to collect the
missing data. The BAI and BDI-II data can be collected
via telephone if it is not possible for the participants to fill
them out by themselves. Information about intervention-
specific services and treatment will be registered by the
care managers and psychiatrists throughout the inter-
vention period.
Safety measures
The following safety measures are collected:
 Self-reported anxiety and depression symptoms
measured with the BAI [45] and BDI-II [47]
 Suicidal ideation obtained from the questions
concerning suicidality in the MINI baseline
eligibility interview [43]
 Death (natural, accident, suicide, homicide/violence
or unknown) obtained from the Danish Register of
Causes of Death [62]
 Life-threatening conditions for reasons other than
suicide attempts obtained from the National Patient
Registry [60]
 Number of physical and mental health outpatient
services, admissions and inpatient days obtained
from the National Patient Registry [60]
 Number of sickness leave days obtained from the
DREAM database [63]
Training and inter-rater reliability
Trained research assistants will perform the baseline
eligibility interviews as well as the objective assessments.
Based on sound records, inter-rater reliability is assessed
throughout the training and assessment period and
discrepancies are discussed with the other raters and at
least one of the intervention developers. In the first 3
months, bi-monthly or monthly meetings are held to dis-
cuss potential difficulties in rating the objective measures of
the PSP scale and the GAF-F scale. Subsequently, reliability
ratings related to these measures are performed approxi-
mately every 3 months throughout the assessment period.
Power and sample size calculation
Differences in clinically relevant treatment response for
the primary outcome measure BAI is set at 4 points
based on international academic literature for the BDI
[67, 68], as academic literature on the BAI could not be
found. International academic literature suggests that a
standard deviation (SD) of 12 for the BAI can be used in
the sample size calculation [36, 68, 69]. The intraclass
correlation coefficient (ICC) is set at 0.04 based on a
review on ICC for anxiety and depression and other
mental disorders in primary care [70]. Sample size calcu-
lations based on these numbers show that 364 persons
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for each trial on panic disorder, generalised anxiety
disorder and social phobia should be included in order
to reject the null hypothesis that the intervention and
control groups have improved their symptom level
equally when the power is set at 0.8 and the significance
level at 0.05.
Power calculations for the secondary outcomes have
been estimated to be more than 0.8 based on calcula-
tions with 182 participants in each group (see Table 1).
As we have not been able to find estimates for the BDI-
II and the GAF-F for patients with anxiety disorders in
general practice, estimates for patients with depression
in general practice have been used as reference for
power calculations for the BDI-II [36], whereas patients
with social phobia recruited from psychiatric clinics have
been used as reference for power calculations for the
GAF-F [71]. Estimates for the SCL-90-R are based on a
mixed anxiety and depression population in an out-
patient setting [72].
Statistical analyses
Data analyses will be carried out according to the statis-
tical principle ‘intention-to-treat’ [73]; thus, once a per-
son meeting the eligibility criteria is included in the
study the person stays in the study population, including
follow-up, regardless of whether the person later meets
the exclusion criteria. All continuous outcome measures
will be analysed using generalised linear models. Multi-
level, linear mixed models with repeated measures will
be used to handle the cluster-randomisation and un-
equal loss to follow-up. The models will be estimated
using an unstructured covariance matrix if possible. If
not possible, other covariance matrices, such as inde-
pendent, interchangeable, autoregressive, and Toeplitz,
will be estimated, and the best fitting structure selected
based on Bayes’ information criterion. The analysis levels
are: GP, patient and time. This model is based on the as-
sumption that data are missing at random or missing
completely at random. Explorative subgroup analyses
will be made for patients with somatic comorbidity and
personality disorders.
Feasibility
Twelve months’ prevalence rates, based on a meta-
analysis including studies conducted in European
countries [74], indicate that a GP with 1600 registered
patients will on average see 37 patients with panic dis-
order, 24 patients with generalised anxiety disorder and
32 patients with social phobia per year. By including a
minimum of 48 GPs in each trial we find it realistic to
include 364 patients with panic disorder, 364 patients
with generalised anxiety disorder and 364 patients with
social phobia, adding up to a total of 1092 patients.
Thus, each GP should recruit approximately seven to
eight patients with each anxiety disorder over a 12-
month period. With a conservative caseload of 100 pa-
tients per care manager per year (25 at a time) and eight
care managers, it should be possible in terms of capacity
to include up to 1600 patients in the study during 12
months of which 800 would be in the intervention
group.
Because there is a risk of GP dropout it might be ne-
cessary to reduce the number of GPs to 44. This affects
the sample size calculations for the trials and thereby
the number of patients needed to include. Thus, 374
participants are required in each of the three trials and
each GP should recruit eight to nine patients with each
anxiety disorder.
Project organisation
The project is led by a steering group which ensures the
progress of the research project. A lead project manager
will ensure that the general management of the project
together with a project manager in charge of implemen-
tation of the intervention and a project manager in
charge of the research project. Administrative staff
members support the project managers. Two PhD stu-
dents and research assistants perform data collection
and analyses.
Discussion
The design of the trials presents several strengths. The
randomisation is carried out externally and is computer
based which ensures an adequate allocation sequence
and concealment, thus reducing the risk of (cluster)
selection bias. In order to further limit the risk of selec-
tion bias, data will be analysed according to the
intention-to-treat principle and attempts to increase
follow-up rates will be made. Also, the trials are rando-
mised at cluster level in an attempt to eliminate the
Table 1 Power calculations for the secondary outcomes
Secondary outcomes Mean difference (MD) Standard deviation (SD)
of the pooled mean
Type 1 error Calculated power
BDI-II 4 [77] 11 [36, 77] 5% 93%
GAF-F 5a 11 [71] 5% 99%
SCL-90-R 23 [72] 50 [72] 5% 99%
aFor the GAF-F the expected mean difference has been conservatively estimated to be 5 points as this is considered clinically relevant
BDI Beck Depression Inventory, GAF Global Assessment of Functioning, SCL Symptom Checklist
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potential risk of contamination otherwise introduced by
individual randomisation. This risk could be present
where GPs trained in collaborative care principles, and
receiving supervision from a project psychiatrist, would
not be able to differentiate between intervention and
control patients when using their acquired skills and ad-
vice from the psychiatrist, which is likely to affect the re-
sults, and thereby making it more difficult to detect
differences between the intervention and the control
group. To ensure that the intervention is provided as
intended, we monitor fidelity to the Collabri model at
least twice during the intervention period.
The primary outcome is self-reported and patients are
not blinded towards allocation, which might result in
information bias and possibly overestimation of effects
[75]. However, the BAI has been found usable for asses-
sing the severity of anxiety symptoms in patients with
anxiety disorders in a general practice setting [76], and
other outcome measures will be assessor blinded for
allocation; for example, the secondary outcome measure
of psychosocial functioning (GAF-F). A limitation, as a
result of the cluster-randomisation, may be that patients
within a cluster have some similarity and may differ
from patients from other clusters. However, sample size
calculations including an ICC have been carried out,
aiming to reduce this problem. Furthermore, we cannot
be sure that all eligible patients are asked to participate
by their GP, as patients are not systematically screened
for eligibility.
The results of these trials will add to the limited pool
of knowledge about collaborative care for patients with
anxiety disorders. To our knowledge, they will be the
first carried out in a Danish context and the first report-
ing results for generalised anxiety and social phobia
separately.
If the trials show positive results, they could contribute
to the improvement of future treatment for patients with
panic disorder, generalised anxiety disorder or social
phobia in general practice.
Trial status
Recruitment of participants within the clusters is
ongoing and continued until 31 December 2016.
Additional file
Additional file 1: A word file with A Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) Checklist is included as
‘Additional file 1’. (DOC 123 kb)
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